If you want the short answer first: Foundayo is usually the easier pill to take, but Wegovy pill currently has the stronger obesity weight-loss benchmark. As of October 2026, Foundayo’s FDA label says to take it with or without food, and Lilly’s dosing page says there are no water restrictions. Wegovy pill still requires an empty-stomach routine with water only and a 30-minute wait before food, drinks, or other oral medications. [2] [4] [7] [9]
That does not mean Wegovy pill is automatically the better choice for every patient. It means the tradeoff is pretty clear right now:
- Foundayo wins on administration simplicity
- Wegovy pill wins on the current obesity efficacy benchmark
- Neither has a true obesity head-to-head trial proving superiority over the other
If you need the broader background first, keep our Foundayo approval guide, semaglutide guide, and tirzepatide vs. semaglutide comparison open in separate tabs. For Foundayo’s dose steps, drug interactions, and missed-dose rules, see our full Foundayo guide.
What are Foundayo and the Wegovy pill?
Foundayo is the brand name for orforglipron, an oral GLP-1 receptor agonist that the FDA approved on April 1, 2026 for chronic weight management in adults with obesity, or adults with overweight plus at least one weight-related condition. [1]
Wegovy pill is oral semaglutide under the Wegovy brand. The FDA approved Wegovy tablets on December 22, 2025. [11] The current prescribing information, revised in June 2026, covers weight reduction in adults with obesity, or overweight plus a weight-related condition. It also lists a heart indication that Foundayo does not have: reducing the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. [9]
So this is no longer a theoretical comparison. There are now two real oral GLP-1 weight-loss options on the market.
Which pill is easier to take: Foundayo or the Wegovy pill?
This is where Foundayo has the clearest edge.
Foundayo
Foundayo’s official dosing page and FDA label say:
- it is taken once daily
- it starts at 0.8 mg
- it increases after 30-day intervals as tolerated
- it can be taken with or without food, and Lilly says there are no water restrictions [2] [4]
Lilly’s page puts it this way: the pill can be taken any time of day, with “no planning around food or drink.” [2] That means the routine is much closer to a normal daily medication.
Wegovy pill
Wegovy pill also uses once-daily dosing, but the routine is more rigid. Novo Nordisk’s dosing page and current prescribing information say:
- start at 1.5 mg once daily
- increase every 30 days as tolerated (4 mg, then 9 mg) until 25 mg
- take it on an empty stomach in the morning
- use water only, up to 4 ounces
- wait at least 30 minutes before food, beverages, or other oral medications [7] [9]
Novo’s own page gives coffee as an example of a drink to hold until the 30 minutes are up. [7]
For some readers, that is not a minor inconvenience. It can be the whole decision. If you already struggle with morning medication timing, other oral prescriptions, or breakfast routines, Foundayo is the easier product to fit into actual life.
Side-by-side comparison
| Question | Foundayo | Wegovy pill |
|---|---|---|
| Active drug | Orforglipron | Semaglutide |
| FDA approval | April 1, 2026, for chronic weight management [1] | Tablets approved December 22, 2025 [11] |
| Heart (cardiovascular) risk indication | No [4] | Yes, in adults with established cardiovascular disease and obesity or overweight [9] |
| Schedule | Once daily [2] | Once daily [7] |
| Food and water rules | With or without food; no water restrictions on the official dosing page [2] [4] | Empty stomach, water only, then wait at least 30 minutes [7] [9] |
| Dose steps | 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg [4] | 1.5, 4, 9, and 25 mg [9] |
| Main obesity trial result on the FDA label | 11.1% average weight loss at 72 weeks on 17.2 mg [4] | 13.6% average weight loss at 64 weeks on 25 mg [9] |
| Closest direct oral-vs-oral evidence | ACHIEVE-3 favored orforglipron over oral semaglutide in type 2 diabetes, not obesity [6] | Same caveat: no direct obesity head-to-head with Foundayo [6] |
| Self-pay price, checked October 25, 2026 | $149 (0.8 and 2.5 mg), $199 (5.5 mg), $299 (9, 14.5, and 17.2 mg); the 2.5 and 5.5 mg prices are temporary through December 31, 2026, and the top two doses cost $349 if a refill is more than 45 days late [3] | $149 (1.5 mg), $199 (4 mg), $299 (9 and 25 mg) [10] |
| Commercial savings card | As little as $25 if your plan covers Foundayo [3] | As little as $25, with maximum savings of $100 a month [10] |
| Medicare GLP-1 Bridge | Covered: $50 a month for eligible Part D enrollees [12] [13] | Covered: $50 a month for eligible Part D enrollees [12] [13] |
Which pill causes more weight loss?
This is the part that needs the most discipline. There is no obesity head-to-head trial showing Foundayo versus Wegovy pill. So the comparison below is cross-trial, not a direct proof test.
Foundayo’s current obesity evidence
The strongest peer-reviewed Foundayo obesity trial is ATTAIN-1, published in the New England Journal of Medicine in 2025. It used an investigational version of the tablet, so the paper names its doses 6 mg, 12 mg, and 36 mg. The FDA label reports the same results as the equivalent Foundayo doses. In adults with obesity without diabetes, the mean body-weight change at 72 weeks was:
- -7.4% with 5.5 mg (6 mg in the paper)
- -8.3% with 9 mg (12 mg in the paper)
- -11.1% with 17.2 mg (36 mg in the paper)
- -2.1% with placebo [4] [5]
At the top dose, 54.5% of participants lost at least 10% of body weight, 35.9% lost at least 15%, and 18.4% lost at least 20%. [4]
That is real efficacy. It is not weak. It just does not currently look like the strongest oral obesity benchmark.
Wegovy pill’s current obesity evidence
The Wegovy label’s tablet trial ran 64 weeks in 307 adults with obesity, or overweight plus a weight-related condition, without type 2 diabetes. Average weight loss was 13.6% on 25 mg, versus 2.4% on placebo. Novo Nordisk’s results page rounds this to about 14%, or about 33 lb. [8] [9]
On 25 mg versus placebo, the label reports:
- 76.3% vs. 31.3% lost at least 5%
- 59.8% vs. 14.4% lost at least 10%
- 47% vs. 5.5% lost at least 15%
- 27.9% vs. 3.1% lost at least 20% [9]
That is the stronger obesity signal right now.
So which oral GLP-1 looks stronger?
If you compare the current obesity-specific benchmark numbers, Wegovy pill looks stronger.
If you compare administration burden, Foundayo looks easier.
If you want the cleanest one-line answer, it is this:
Foundayo looks easier to stick with. Wegovy pill looks stronger for average weight loss.
That is still not the same thing as saying one is globally “better.” Different patients care about different tradeoffs. The two trials also ran for different lengths (72 weeks vs. 64 weeks) in different groups of people, which is one more reason not to treat a 2.5-point gap as a ranking.
Has Foundayo been tested head to head against oral semaglutide?
Lilly’s ACHIEVE-3 trial is important because it gave us the first direct comparison between orforglipron and oral semaglutide. But it enrolled adults with type 2 diabetes on metformin, not adults using the obesity labels. Lilly’s release says participants on orforglipron 36 mg lost 9.2% of body weight versus 5.3% with oral semaglutide 14 mg over 52 weeks. Counting everyone who was randomized, the figures were 8.2% versus 5.3%. [6]
That matters because it suggests orforglipron may compete well against oral semaglutide in a direct oral-versus-oral setting. But it does not settle the Foundayo-versus-Wegovy-pill question for obesity treatment because:
- the population was different
- the doses were different: the oral semaglutide doses tested were 7 mg and 14 mg, not the 25 mg Wegovy pill dose
- the endpoint context was diabetes treatment, not the current obesity label comparison
Use ACHIEVE-3 as supporting context, not as the final verdict.
Which pill has fewer side effects?
Foundayo’s biggest advantage is convenience, not a gentler side-effect profile.
The current Foundayo label says pooled gastrointestinal adverse reactions occurred in:
- 60% of patients on Foundayo 5.5 mg
- 68% on 9 mg
- 69% on 17.2 mg
- versus 37% with placebo [4]
Discontinuations due to GI side effects were also higher with Foundayo than placebo. [4]
The labels also report how many people stopped treatment because of side effects. In the Foundayo trials, 8% stopped, versus 3% on placebo. In the Wegovy tablet trial, 6.9% stopped, versus 5.9% on placebo. These come from different trials, so the gap is a clue, not proof that one pill is easier on the stomach. [4] [9]
The Wegovy Medication Guide, which covers both the pill and the shot, says the most common side effects may include:
- nausea
- diarrhea
- vomiting
- constipation
- stomach pain
- changes in skin sensations
- headache
- fatigue
- upset stomach
- dizziness
- bloating
- belching
- gas
- stomach flu
- heartburn
- hair loss
- low blood sugar in people with type 2 diabetes [9]
The honest comparison is not “Foundayo has fewer side effects because it is a pill.” The honest comparison is:
- both are still GLP-1 medicines
- both can cause the usual GI problems
- Foundayo mainly wins on convenience, not on proof that it is easier to tolerate
If side effects are your biggest concern, read our broader GLP-1 side effects guide before deciding that either oral option solves the problem.
Which pill costs less in 2026?
This section needs dates because these programs are mutable. All prices below were checked on October 25, 2026.
Foundayo
Foundayo’s public savings page shows a self-pay price for every dose: [3]
- $149 for 0.8 mg
- $149 for 2.5 mg (temporarily reduced through December 31, 2026; regular price $199)
- $199 for 5.5 mg (temporarily reduced through December 31, 2026; regular price $299)
- $299 for 9 mg
- $299 for 14.5 mg and 17.2 mg if you refill within 45 days; otherwise $349
The same page says patients whose commercial plan covers Foundayo may pay as little as $25 for a 1-, 2-, or 3-month fill, with savings capped at $100 a month. [3]
Wegovy pill
Novo’s pricing page says self-pay patients pay $149 a month for 1.5 mg, $199 for 4 mg, and $299 for 9 mg and 25 mg, with one month defined as one bottle of 30 tablets. Commercially insured patients may pay as little as $25 a month, subject to maximum savings of $100 a month, and government beneficiaries are excluded. [10]
Medicare and TrumpRx
Both pills are on the list of drugs covered by the Medicare GLP-1 Bridge, a CMS program that runs from July 1, 2026 through December 31, 2027. Eligible Part D enrollees pay a $50 monthly copay, after a prior authorization. [12] [13] TrumpRx.gov also lists both pills, at the same self-pay prices shown above. [14] [15]
What that means in plain English
On self-pay price, the two pills are now close: both start at $149 a month and top out at $299, as long as Foundayo’s top doses are refilled on time. Foundayo’s low 2.5 mg and 5.5 mg prices are temporary cuts that end December 31, 2026, so its middle steps could cost more next year. Neither page tells you exactly what your long-term out-of-pocket cost will be after insurance rules, pharmacy channel, and dose escalation all play out.
If cost is your main constraint, also review our insurance guide, cheapest way to get GLP-1s in 2026, and our guide to where to get Foundayo.
Which pill is the better fit for you?
Foundayo may be the better fit if:
- you want the lowest routine burden
- you dislike injections and also dislike rigid empty-stomach medication rules
- you take other morning pills and do not want a 30-minute separation routine
- you care a lot about daily convenience even if the obesity benchmark is a bit weaker [2] [4]
Wegovy pill may be the better fit if:
- you want the stronger current obesity benchmark
- you are willing to follow a stricter morning routine
- you want an oral semaglutide option specifically and can manage the absorption rules
- you have established cardiovascular disease and want a pill whose label includes lowering the risk of heart attack and stroke [7] [8] [9]
Neither answer should be oversold
If you want the most aggressive weight-loss benchmark overall, weekly injectables can still look stronger than either oral option in current obesity trials. That is why the decision is rarely just “pill good, shot bad.” It is usually a compromise between effect size, routine burden, tolerability, and cost.
The bottom line
As of October 2026, the best evidence-based answer is:
- choose Foundayo if daily simplicity is the main priority
- choose Wegovy pill if the stronger current oral obesity benchmark, or its heart-risk indication, matters more than routine convenience
- treat any stronger claim than that as overconfident, because the obesity head-to-head trial does not exist yet
That is not an unsatisfying answer. It is the honest one.
